AlloVir, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALVR research report →
Price Chart
About the company
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections.
- CEO
- Vikas Sinha CPA,
- IPO
- 2020
- Employees
- 6
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on ALVR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $49.48M
- P/E
- -1.24
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 1.03
- EV/EBITDA
- -0.28
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -71.71%
- ROIC
- -52.40%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-46,152,000
- Net Income
- $-43,438,000+26.1%
- EPS
- $-2.85+75.7%
- OCF Growth
- +43.3%
- FCF Growth
- +43.0%
- 52W High
- $24.15
- 52W Low
- $7.96
- 50D MA
- $9.73
- 200D MA
- $14.55
- Beta
- 0.62
- RSI (14)
- 51
- Avg Volume
- 22.94K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Alvarion reported a smaller Q4 loss and improved cash, while accelerating its pivot to unlicensed broadband and Wi-Fi after agreeing to sell its carrier licensed division.· March 4, 2013
- Q4 revenue was $8.2 million, down from $10.9 million in Q4, while non-GAAP gross margin was 38.2% versus 46.5% in Q3.
- Non-GAAP operating expenses fell to $7.1 million from $7.6 million in Q3; management said Q1 2013 expenses should stay similar to Q4 and then decline slightly.
- Cash, cash equivalents and investments were $40.4 million at December 31, and debt declined to $11 million from $13 million at the start of the year.
- The company agreed to sell its carrier licensed business to Telrad Networks and will focus on unlicensed solutions, especially vertical networks and carrier Wi-Fi.
- Management said the break-even point is around $11.5 million of revenue and $6-7 million of expenses, and expects gross margin to return to about Q3 levels.
Q4 revenue was $8.2 million, down from $10.9 million in Q4. Non-GAAP gross margin was 38.2% compared with 46.5% in Q3. GAAP operating expenses were $7.9 million; non-GAAP operating expenses were $7.1 million versus $7.6 million in Q3. GAAP net loss from continuing operations was $0.08 per share, non-GAAP net loss was $0.07 per share, and net loss from discontinued operations was $0.19 per share. Cash, cash equivalents and investments, including restricted cash, totaled $40.4 million as of December 31. Cash generated from operations was $454,000 versus cash used of $6.4 million in Q3. Cash used from continuing operations was $5.3 million. Inventory was $9.3 million and DSOs were 115 days. Forward-looking commentary: Q1 2013 operating expenses are expected to remain similar to Q4 levels and decline slightly in later quarters; gross margin for the unlicensed business is expected to be around Q3 levels; management said the break-even point is around $11.5 million of revenue and $6-7 million of expenses.
Hezi Lapid framed the sale of the DWA/carrier licensed division as the best strategic outcome given market conditions and limited resources, saying the company should focus on the unlicensed segment where it sees the most growth opportunity. He emphasized the turnaround plan: lower burn, more efficient sales channels, new value-added partners, and investment in Wi-Fi products and collaborations. His tone was cautious but constructive, repeatedly noting that the company is still not profitable, but that profitability is achievable.
Avi Stern said the reported financials now largely reflect the vertical and unlicensed carrier solutions business, with the carrier licensed business shown as discontinued operations after the Telrad deal. He highlighted the quarter’s $8.2 million of revenue, 38.2% non-GAAP gross margin, $7.1 million of non-GAAP operating expenses, and $40.4 million of cash and investments at quarter-end. He also said debt was down to $11 million from $13 million at the beginning of the year, cash generated from operations was $454,000, and Q1 2013 operating expenses should stay near Q4 levels before edging down later.
Analysts pressed management on whether the $8.2 million revenue run rate was the bottom and whether Wi-Fi revenue met prior expectations. Hezi Lapid declined to give revenue guidance but said he would be disappointed if this was not the floor, and he said the delay in the new WBSn version did not hurt second-half 2012 results, though the company would not break out product-line revenue. Questions also focused on margins and break-even; management said mid-40s gross margin should return with better volume, but Hezi rejected the idea that the quarter was already structurally break-even and said more disclosure would not fix the NASDAQ listing issue.
The company is exiting a lower-priority business and concentrating on the unlicensed market, where management sees the most significant growth opportunities. They cited new partner agreements across Africa, Asia and Australia, product upgrades, and active deployments and trials in carrier Wi-Fi and vertical markets as reasons for optimism.
The business is still not profitable, revenue fell quarter over quarter, and management acknowledged there is still significant work to do. The company also faces a NASDAQ compliance deadline by April 22 and plans a reverse split, which underscores the pressure on the share price and operating performance. Management would not provide detailed revenue guidance, and analysts probed whether the reported revenue and margin levels might still be weakening rather than stabilizing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 17.3%
- Shares Outstanding
- 5.04M
- Float Shares
- 873.06K
of shares held by institutions
62 13F filers
Buy/sell ratio 0.05. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 634.02K | ▼ 2.75M |
| Raymond James Financial Services Advisors, Inc. | 60.50K | 0 |
| Focus Financial Network Inc /Adv | 32.14K | ▲ 32.14K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 21, 25 | Sinha Vikas | sell | 303 |
| Feb 21, 25 | Hagen Brett R | sell | 96 |
| Feb 21, 25 | Miller Edward | sell | 106 |
| Jan 23, 25 | Miller Edward | sell | 47 |
| Jan 23, 25 | Miller Edward | sell | 5 |
| Jan 23, 25 | Hagen Brett R | sell | 32 |
| Jan 23, 25 | Hagen Brett R | sell | 4 |
| Jan 23, 25 | Sinha Vikas | sell | 116 |
| Jan 23, 25 | Sinha Vikas | sell | 13 |
| Jan 10, 25 | Miller Edward | sell | 409 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALVR coverage
Recent articles, reports, and earnings notes.
No research on ALVR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALVR report →KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders
globenewswire.com · Aug 3
Head to Head Review: AlloVir (NASDAQ:ALVR) versus SQZ Biotechnologies (NYSE:SQZ)
defenseworld.net · Oct 31
ALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term Stockholders
globenewswire.com · Oct 16
ALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
globenewswire.com · Aug 6
Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Stockholders to Inquire about Securities Investigation
accessnewswire.com · Jun 15
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Investors to Learn More About the Investigation
accessnewswire.com · Jun 12
AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
accessnewswire.com · Jun 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.